Almac Diagnostics Limited
Records under this name other than patents Almac Diagnostics Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Almac Diagnostics Limited
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,677,140 | Molecular diagnostic test for cancer Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,670,547 | Molecular diagnostic test for cancer Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,378,066 | Molecular diagnostic test for cancer Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,214,777 | Molecular diagnostic test for cancer Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,254,986 | Gene signature for immune therapies in cancer Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,091,809 | Molecular diagnostic test for cancer Lapsed on the fee record Ended Aug 17, 2025 · From the USPTO record | Lapsed on the fee record | Ended Aug 17, 2025 | From the USPTO record |
| US 10,280,468 | Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer Formerly held Lapsed on the fee record Ended May 7, 2023 · From the USPTO record | Lapsed on the fee record | Ended May 7, 2023 | From the USPTO record |
| US 10,260,097 | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent Formerly held Lapsed on the fee record Ended Apr 16, 2023 · High confidence | Lapsed on the fee record | Ended Apr 16, 2023 | High confidence |
| US 10,196,691 | Colon cancer gene expression signatures and methods of use Formerly held Lapsed on the fee record Ended Feb 5, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 5, 2023 | From the USPTO record |
| US 10,196,697 | Prostate cancer classification Formerly held Lapsed on the fee record Ended Feb 5, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 5, 2023 | From the USPTO record |